# US 2025/0084128 A1 · ANTIVIRAL STRUCTURALLY-STAPLED SARS-CoV-2 PEPTIDE-CHOLESTEROL CONJUGATES AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084128 A1
- Document ID: US20250084128A1
- Status: Published application
- Kind: A1
- Application number: 18/689,565
- Filed: 2022-09-08
- Published: 2025-03-13
- Earliest claimed: 2021-09-08
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Loren D. Walensky; Gregory H. Bird
- Web page: https://patentgrep.com/patent/US20250084128A1

## CPC

- C07K 14/005: from viruses
- A61K 9/0043: {Nose}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 39/12: Viral antigens
- A61K 47/554: {the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 31/14: for RNA viruses
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are cross-linked peptides either alone or conjugated to PEG(n)-cholesterol (or thiocholesterol) moieties useful for interfering with and inhibiting or preventing coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19.

## Claims

### Claim 1

A structurally-stabilized peptide comprising an amino acid sequence that is at least 85% identical to sequence set forth in SEQ ID NO: 6 (DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGK), wherein amino acids at positions of SEQ ID NO:6 selected from (wherein position 1 is the N-terminal Aspartic Acid and position 38 is the C-terminal Lysine of SEQ ID NO: 6):
(i) positions 14 and 21,
(ii) positions 17 and 24,
(iii) positions 21 and 28, or
(iv) positions 24 and 31;
are replaced by α, α-disubstituted non-natural amino acids with olefinic side chains whose side chains are cross-linked;
wherein the structurally-stabilized peptide is 38 to 60 amino acids in length; and
wherein the structurally-stabilized peptide inhibits infection of a cell by SARS-CoV-2 in pseudovirus and/or live SARS-CoV-2 virus assays and/or wherein the structurally-stabilized peptide prevents infection of a cell by SARS-CoV-2 in the pseudovirus and/or the live SARS-CoV-2 virus assays.

### Claim at position 2

-14. (canceled)

### Claim 15 (depends on 1)

A conjugate comprising the structurally-stabilized peptide of claim 1 and (i) polyethylene glycol (PEG) and/or (ii) cholesterol or thiocholesterol, wherein the (i) PEG and/or (ii) cholesterol or thiocholesterol are linked to the C-terminus of the structurally-stabilized peptide.

### Claim at position 4

-28. (canceled)

### Claim 29

A conjugate comprising:
a structurally-stabilized peptide of SEQ ID NO: 10 (DISGINASVVNIQ8EIDRLNXVAKNLNESLIDLQELGK), wherein 8 is a (R)-α-(7′-octenyl)alanine group or a (R)-α-(4′-pentenyl)alanine group, and X is a (S)-α-(4′-pentenyl)alanine group or a (S)-α-(7′-octenyl)alanine group; and
a PEG(n)-cholesterol or a PEG(n)-thiocholesterol moiety linked to the C-terminal lysine of the structurally-stabilized peptide, wherein n is 1-36.

### Claim at position 6

-40. (canceled)

### Claim 41

A structurally-stabilized peptide comprising the formula:
or a pharmaceutically acceptable salt thereof, wherein:
each R1 and R2 is H or a C1 to C10 alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl, any of which is substituted or unsubstituted;
each R3 is independently alkylene, alkenylene, or alkynylene, any of which is substituted or unsubstituted;
z is 1;
(a) each [Xaa]w is DISGINASVVNIQ (SEQ ID NO: 35), each [Xaa]x is EIDRLN (SEQ ID NO: 36), and each [Xaa]y is VAKNLNESLIDLQELGK (SEQ ID NO: 37);
(b) each [Xaa]w is DISGINASVVNIQKEI (SEQ ID NO: 44), each [Xaa]x is RLNEVA (SEQ ID NO: 45), and each [Xaa]y is NLNESLIDLQELGK (SEQ ID NO: 46);
(c) each [Xaa]w is DISGINASVVNIQKEIDRLN (SEQ ID NO: 56), each [Xaa]x is VAKNLN (SEQ ID NO: 57), and each [Xaa]y is SLIDLQELGK (SEQ ID NO: 58); or
(d) each [Xaa]w is DISGINASVVNIQKEIDRLNEVA (SEQ ID NO: 65), each [Xaa]x is NLNESL (SEQ ID NO: 66), and each [Xaa]y is DLQELGK (SEQ ID NO: 67); and
wherein the structurally-stabilized peptide inhibits infection of a cell by SARS-CoV-2 in in pseudovirus and/or live SARS-CoV-2 virus assays and/or wherein the structurally-stabilized peptide prevents infection of a cell by SARS-CoV-2 in the pseudovirus and/or the live SARS-CoV-2 virus assays.

### Claim at position 8

-49. (canceled)

### Claim 50

A structurally stabilized peptide comprising Formula I-A, wherein Formula I-A is defined by:
or a pharmaceutically acceptable salt thereof;
R3 is alkenylene;
[Xaa]w is
(SEQ ID NO: 35)
DISGINASVVNIQ;
[Xaa]x is
(SEQ ID NO: 36)
EIDRLN;
and
[Xaa]y is
(SEQ ID NO: 37)
VAKNLNESLIDLQELGK;
wherein optionally the amino group of the N-terminal aspartic acid in [Xaa]w is replaced with —N(H)C(O)—(C1-4 alkyl), and optionally the carboxylic acid group of the C-terminal lysine in [Xaa]y is replaced with —C(O)NH2.

### Claim at position 10

-64. (canceled)

### Claim 65 (depends on 41)

A conjugate comprising the structurally-stabilized peptide or pharmaceutically acceptable salt thereof of claim 41 and (i) PEG and/or (ii)cholesterol or thiocholesterol.

### Claim 66 (depends on 50)

A conjugate comprising the structurally-stabilized peptide or pharmaceutically acceptable salt thereof of claim 50 and (i) PEG and/or (ii) cholesterol or thiocholesterol.

### Claim at position 13

-121. (canceled)

### Claim 122

A method of making a structurally-stabilized peptide, the method comprising: (a) providing a peptide having the sequence set forth in SEQ ID NO: 6 or a variant thereof, and (b) cross-linking the peptide.

### Claim at position 15

123-124. (canceled)

### Claim 125

A method of synthesizing a conjugate comprising a heptad repeat domain 2 (HR2) polypeptide, the method comprising (a) providing the HR2 polypeptide; and (b) derivatizing a resin bound amine of the HR2 polypeptide with (i) PEG and/or (ii) cholesterol or thiocholesterol containing a carboxylic acid on a resin.

### Claim at position 17

-150. (canceled)

### Claim 151

A linker comprising:
(a) a PEG(n)-thiocholesterol comprising the formula:
wherein n is 1-36; or
(b) a PEG(n)-cholesterol comprising the formula:
wherein n is 1-36.

### Claim at position 19

-154. (canceled)

### Claim 155 (depends on 1)

A pharmaceutical composition comprising the structurally-stabilized peptide of claim 1, and a pharmaceutically acceptable carrier.

### Claim 156 (depends on 41)

A pharmaceutical composition comprising the structurally-stabilized peptide of claim 41, and a pharmaceutically acceptable carrier.

### Claim 157 (depends on 50)

A pharmaceutical composition comprising the structurally-stabilized peptide of claim 50, and a pharmaceutically acceptable carrier.

### Claim 158 (depends on 15)

A pharmaceutical composition comprising the conjugate of claim 15, and a pharmaceutically acceptable carrier.

### Claim 159 (depends on 29)

A pharmaceutical composition comprising the conjugate of claim 29, and a pharmaceutically acceptable carrier.

### Claim 160 (depends on 65)

A pharmaceutical composition comprising the conjugate of claim 65, and a pharmaceutically acceptable carrier.

### Claim 161 (depends on 66)

A pharmaceutical composition comprising the conjugate of claim 66, and a pharmaceutically acceptable carrier.

### Claim 162 (depends on 1)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the structurally-stabilized peptide of claim 1, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 163 (depends on 41)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the structurally-stabilized peptide of claim 41, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 164 (depends on 50)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the structurally-stabilized peptide of claim 50, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 165 (depends on 15)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the conjugate of claim 15, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 166 (depends on 29)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the conjugate of claim 29, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 167 (depends on 65)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the conjugate of claim 65, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 168 (depends on 66)

A method of treating a coronavirus infection in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of the conjugate of claim 66, wherein the subject is selected from a human, a cow, a pig, a horse, a cat, a dog, a rat, a mouse, or a bat.

### Claim 169 (depends on 1)

A nanoparticle composition comprising the structurally-stabilized peptide of claim 1.

### Claim 170 (depends on 41)

A nanoparticle composition comprising the structurally-stabilized peptide of claim 41.

### Claim 171 (depends on 50)

A nanoparticle composition comprising the structurally-stabilized peptide of claim 50.

### Claim 172 (depends on 15)

A nanoparticle composition comprising the conjugate of claim 15.

### Claim 173 (depends on 29)

A nanoparticle composition comprising the conjugate of claim 29.

### Claim 174 (depends on 65)

A nanoparticle composition comprising the conjugate of claim 65.

### Claim 175 (depends on 66)

A nanoparticle composition comprising the conjugate of claim 66.
